The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

Palivizumab, when given through the veins or into a muscle (systemically), reduces hospitalisations due to respiratory syncytial virus (RSV) and reduces respiratory problems later on (chest wheezing), ...

Killing on average over 100,000 children across the world per year, respiratory syncytial virus (RSV) is the second greatest cause of death by a single pathogen for children under one year of age ...

Respiratory Syncytial Virus (RSV) is a leading cause of lower respiratory tract infections worldwide, recently there has been a surge in interest in RSV antigens, antibodies, and more in ...

In a retrospective study published in the Journal of the American Geriatrics Society, adults aged 65 and older hospitalized for RSV in Ontario, Canada experienced significantly higher rates of adverse ...

Respiratory syncytial virus (RSV) causes symptoms similar to the common cold. But in older adults and those with certain medical conditions, the virus can increase the risk of serious illnesses. A ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis . 2004;190(2):373-378. doi:10.1086/421524 Barnes MVC, Openshaw PJM, Thwaites RS.